The Jackson Laboratory–New York Stem Cell Foundation Collaborative (JAX-NYSCF) has entered into a five-year research partnership with GSK to advance the development of human cellular models for neurodegenerative diseases, including Alzheimer’s disease.
This initiative aims to bridge the gap between scientific discovery and the creation of new treatments. The collaboration will combine expertise in stem cell research, data science, and large-scale research systems to create disease-relevant cellular models. These models are intended to help researchers better understand the biology underlying neurodegenerative conditions and speed up the process of turning these insights into potential therapies.
Lon Cardon, president and CEO of JAX, commented on the partnership: "This collaboration is a concrete example of where early stage biomedical research is heading. Now we have the opportunity to extend those discoveries -and accelerate therapies to patients-by bridging traditional disease models with next-generation patient-derived induced pluripotent stem cell (iPSC) models that more accurately capture the complexity of human biology at scale."
The joint effort will leverage GSK’s experience in neurodegeneration and drug discovery along with JAX-NYSCF’s advanced stem cell technology, access to patient cohorts, and automation capabilities. The goal is to develop more predictive models for identifying and prioritizing drug candidates for neurodegenerative diseases.
